Etiology of cardiovascular disease in patients with schizophrenia: Current perspectives

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2493-2503

  Emul, Murat ^a   Kalelioglu, Tevfik ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Neurological Disorders   (Turkey)

Author keywords

Antipsychotic; Cardiovascular risk; MetS; miRNA; QTc; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; MICRORNA; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ATRIAL FIBRILLATION; CARDIOMETABOLIC RISK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG SAFETY; EPIGENETICS; GENETIC ASSOCIATION; HEART DEATH; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; P WAVE; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN CARDIAC DEATH; TORSADE DES POINTES;

EID: 84943370283     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S50006     Document Type: Review

References (77)

1. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609–616.
2. Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014; 71(12):1350–1363.
3. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease–a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry. 2014;5:137.
4. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry. 2003;160(2):284–289.
5. Raphael TP, Parsons JP. Blood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatry. 1921;5:687–709.
6. Hansen T, Ingason A, Djurovic S, et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011;70(1):59–63.
7. Le Hellard S, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry. 2009;14(3):308–317.
8. Liou YJ, Bai YM, Lin E, et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J. 2012;12(1):54–61.
9. Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res. 2011;125(2–3):179–186.
10. Burghardt K, Grove T, Ellingrod V. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J Psychopharmacol. 2014;28(4):349–356.
11. Chen X, Lee G, Maher BS, et al; GROUP Investigators; International Schizophrenia Consortium. GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol Psychiatry. 2011;16(11):1117–1129.
12. Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry. 2010;67(10):991–1001.
13. Meyer D, Birchmeimer C. Multiple essential functions of neuregulin in development. Nature. 1995;378(6558):386–390.
14. Huertas-Vazquez A, Teodorescu C, Reinier K, et al. A common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death. Heart Rhythm. 2013;10(7):994–998.
15. Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012;12(2):165–172.
16. Seven M, Karatas OF, Duz MB, Ozen M. The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncol. 2014;10(6):1027–1048.
17. de Bartolomeis A, Iasevoli F, Tomasetti C, Buonaguro EF. MicroRNAs in schizophrenia: implications for synaptic plasticity and dopamine-glutamate interaction at the postsynaptic density. New avenues for antipsychotic treatment under a theranostic perspective. Mol Neurobiol. Epub 2014 Nov 14.
18. Perkins DO, Jeffries CD, Jarskog LF, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007;8(2):R27.
19. Gardiner E, Beveridge NJ, Wu JQ, et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry. 2012;17(8): 827–840.
20. Santarelli DM, Liu B, Duncan CE, et al. Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine. Psychopharmacology (Berl). 2013;227(1):67–78.
21. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incidence cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–414.
22. Hanley AJ, Karter AJ, Williams K, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation. 2005;112(24): 3713–3721.
23. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry. 2007;68(11):1793–1798.
24. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58–62.
25. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci. 2004;74(16):1999–2008.
26. Fleischhacker WW, Siu CO, Bodén R, et al; EUFEST Study Group. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol. 2013;16(5):987–995.
27. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306–318.
28. Van Gaal LF. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol. 2006;16(suppl 3):S142–S148.
29. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287(3):356–359.
30. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.
31. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53.
32. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26(4):903–912.
33. Kuehn BM. Questionable antipsychotic prescribing remains common, despite serious risks. JAMA. 2010;303(16):1582–1584.
34. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010;23(6):574–581.
35. Arranz B, San L, Dueñas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol. 2007;22(1):11–15.
36. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060.
37. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21(2):93–98.
38. Bär KJ. Cardiac autonomic dysfunction in patients with schizophrenia and their healthy relatives–a small review. Front Neurol. 2015;6:139.
39. Emul M, Dalkiran M, Coskun O, et al. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. Pharmacol Res. 2009;60(5):369–372.
40. Toichi M, Kubota Y, Murai T, et al. The influence of psychotic states on the autonomic nervous system in schizophrenia. Int J Psychophysiol. 1999;31(2):147–154.
41. Bär KJ, Berger S, Metzner M, et al. Autonomic dysfunction in unaffected first-degree relatives of patients suffering from schizophrenia. Schizophr Bull. 2010;36(5):1050–1058.
42. Jindal RD, Keshavan MS, Eklund K, Stevens A, Montrose DM, Yeragani VK. Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naïve psychosis. Schizophr Res. 2009;113(2–3):176–180.
43. Valkonen-Korhonen M, Tarvainen MP, Ranta-Aho P, et al. Heart rate variability in acute psychosis. Psychophysiology. 2003;40(5):716–726.
44. Vrtovec B, Starc V, Starc R. Beat-to-beat QT interval variability in coronary patients. J Electrocardiol. 2000;33(2):119–125.
45. Chung AK, Chua SE. Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25(5):646–666.
46. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia and sudden death. J Clin Psychopharmacol. 2003;23(1):58–77.
47. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65(11):1029–1038.
48. Zhao T, Park TW, Yang JC, et al. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Int Clin Psychopharmacol. 2012;27(4):184–190.
49. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048–1052.
50. Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 1996;93(4):311–313.
51. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62–69.
52. Yang FD, Wang XQ, Liu XP, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 2011;216(1):9–16.
53. Suzuki Y, Sugai T, Fukui N, et al. Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Hum Psychopharmacol. 2013;28(3):215–219.
54. Ozeki Y, Fujii K, Kurimoto N, et al. QTc prolongation and antipsychotic medications in a sample of 1, 017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):401–405.
55. Ramos-Ríos R, Arrojo-Romero M, Paz-Silva E, et al. QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res. 2010;116(1):35–43.
56. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10): 887–920.
57. Suzuki Y, Ono S, Tsuneyama N, et al. Effects of olanzapine on the PR and QT intervals in patients with schizophrenia. Schizophr Res. 2014;152(1):313–314.
58. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA. 2009;301(24):2571–2577.
59. Bayar R, Emül M, Turan S, et al. Electrocardiographical P wave changes after electroconvulsive therapy in patients with schizophrenia: a preliminary study. J ECT. 2009;25(1):26–30.
60. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627.
61. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001;345(3):224–225.
62. Alawami M, Wasywich C, Cicovic A, Kenedi C. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol. 2014;176(2):315–320.
63. Reinders J, Parsonage W, Lange D, Potter JM, Plever S. Clozapine related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry. 2004;38(11–12):915–922.
64. De Berardis D, Serroni N, Campanella D, et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf. 2012;7(1):55–62.
65. Brakoulias V, Bannan E, Cohen P, Geary G. Amisulpride and cardiomyopathy. Aust N Z J Psychiatry. 2005;39(8):738.
66. Bush A, Burgess C. Fatal cardiomyopathy due to quetiapine. N Z Med J. 2008;121(1268):U2909.
67. Roesch-Ely D, Van Einsiedel R, Kathöfer S, Schwaninger M, Weisbrod M. Myocarditis with quetiapine. Am J Psychiatry. 2002; 159(9):1607–1608.
68. Coffey S, Williams M. Quetiapine-associated cardiomyopathy. N Z Med J. 2011;124(1337):105–107.
69. Bhatia MS, Gupta R, Dhawan J. Myocarditis after overdose of conventional antipsychotics. World J Biol Psychiatry. 2009;10(4 pt 2):606–608.
70. Marti V. Sudden cardiac death due to risperidone therapy in a patient with possible hypertrophic cardiomyopathy. Ann Pharmacother. 2005;39(5):973.
71. Tay JK, Tan CH, Chong SA, Tan EC. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1297–1302.
72. Christoforou N, Miller RA, Hill CM, Jie CC, McCallion AS, Gearhart JD. Mouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genes. J Clin Invest. 2008;118(3):894–903.
73. Andreassen OA, Thompson WK, Dale AM. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr Bull. 2014;40(1):13–17.
74. Andreassen OA, Djurovic S, Thompson WK, et al; International Consortium for Blood Pressure GWAS, Diabetes Genetics Replication and Meta-analysis Consortium, Psychiatric Genomics Consortium Schizophrenia Working Group. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92(2): 197–209.
75. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235.
76. van Noord C, Dörr M, Sturkenboom MC, et al. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol. 2010;25(1):21–28.
77. Gupta P, Patel C, Patel H, et al. T (p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol. 2008;41:567–574.